Treatment of Bulimia Nervosa With Ondansetron
- 1 October 1997
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 54 (10) , 969-970
- https://doi.org/10.1001/archpsyc.1997.01830220099014
Abstract
Bulimia nervosa, a chronic psychiatric disorder, is characterized by frequent episodes of binge eating followed by purging (usually in the form of self-induced vomiting) with a loss of volitional control over these behaviors. This disorder occurs in 3% to 5% of young women.1Our research group has previously suggested that the pathophysiological characteristics driving the abnormal behaviors involve an increase in the basal tone of the vagus nerve as a result of repeated and aggressive stimulation of the gastric branch of the vagus nerve by binge eating and vomiting.2This hypothesis led us to treat a total of 5 women who met theDSM-III-Rcriteria for bulimia nervosa (binge-purge subtype) with ondansetron hydrochloride (a 5-hydroxytryptamine type 3 receptor antagonist that pharmacologically decreases vagal transmission3). All of these patients were considered to have severe bulimia nervosa due to the chronicity of the disease, a history of previous drugKeywords
This publication has 2 references indexed in Scilit:
- Nociceptive, but not tactile, thresholds are elevated in bulimia nervosaBiological Psychiatry, 1992
- Studies of the epidemiology of bulimia nervosaAmerican Journal of Psychiatry, 1990